Evidence map›Paper›PMID 26372909›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016

Lupus-Prone Mice Resist Immune Regulation and Transplant Tolerance Induction.

B T Stocks, A J Wilhelm, C S Wilson, A F Marshall, N E Putnam, A S Major, D J Moore

Abstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

B T StocksDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN.
A J WilhelmDepartment of Medicine, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN.
C S WilsonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN.
A F MarshallDepartment of Pediatrics, Ian Burr Division of Endocrinology and Diabetes, Vanderbilt University, Nashville, TN.
N E Putnam
A S MajorDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN.
D J MooreDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Vanderbilt/Meharry Initiative for Minority Student DvptR25GM062459 · NIGMS · VANDERBILT UNIVERSITY · PI VELEZ EDWARDS, DIGNA R · 2002 to 2020
$10.4M
Accelerated Atherosclerosis and system lupus erythematosusR01HL088364 · NHLBI · VANDERBILT UNIVERSITY · PI MAJOR, AMY S · 2008 to 2011
$1.6M
Harnessing B lymphocytes as Antigen-Specific Regulators of Islet ToleranceK08DK090146 · NIDDK · VANDERBILT UNIVERSITY · PI MOORE, DANIEL J. · 2011 to 2013
$434k
Restoration of Immune Tolerance in Type 1 DiabetesR03DK097410 · NIDDK · VANDERBILT UNIVERSITY · PI MOORE, DANIEL J. · 2013 to 2014
$156k
NCATS NIH HHS L40 TR000569NCI NIH HHS P30 CA068485NCI NIH HHS P30-CA68485NHLBI NIH HHS R01 HL088364NHLBI NIH HHS R01-HL088364NIDDK NIH HHS DK-058404NIDDK NIH HHS K08 DK090146NIDDK NIH HHS K08-DK090146NIDDK NIH HHS L40 DK084746NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R03 DK097410NIDDK NIH HHS R03-DK097410NIGMS NIH HHS R25 GM062459NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32-GM07347
6 · The paper itself

Abstract

The strongly immunogenic environment in autoimmune diseases such as lupus may pose a stringent barrier to transplantation. Despite available murine models of lupus, transplant tolerance in this setting has yet to be fully investigated in highly penetrant genetic models of disease. Such studies are of clear clinical importance because lupus is a transplant indication in which transplanted kidneys have a substantially increased risk of rejection including a role for recurrent nephritis. In the fully penetrant B6.SLE123 mouse, we determined that CD4 T follicular helper and germinal center B cells were significantly expanded compared with healthy controls. We traced this expansion to resistance of effector CD4 T and B cells in B6.SLE123 mice to regulation by either CD4 T regulatory cells (CD4Tregs) or CD8 T regulatory cells (CD8Tregs), despite demonstrating normal function by Tregs in this strain. Finally, we determined that B6.SLE123 mice resist anti-CD45RB-mediated tolerance induction to foreign islet allografts, even in the absence of islet autoimmunity. Overall, B6.SLE123 lupus-prone mice are highly resistant to transplant tolerance induction, which provides a new model of failed tolerance in autoimmunity that may elucidate barriers to clinical transplantation in lupus through further cellular and genetic dissection.

Indexed as

AnimalsAutoantibodiesAutoimmunityCells, CulturedDendritic CellsGraft RejectionGraft SurvivalIslets of Langerhans TransplantationLupus Erythematosus, SystemicLupus NephritisMiceMice, Inbred C3HMice, Inbred C57BLMice, Inbred MRL lprMice, Inbred NODT-Lymphocytes, RegulatoryAutoantibodiesalloantibodyautoimmunitybasic (laboratory) research / scienceimmune regulationimmunobiologyislet transplantationT cell biologytolerance: mechanisms

Identifiers

PMID26372909
PMCPMC4718751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.